𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Peripheral blood progenitor cell collections in children


Book ID
109140505
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
217 KB
Volume
39
Category
Article
ISSN
0372-1248

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Determination of optimal timing of perip
✍ R.A. Anderson; T.R. Corr; K.R. Schultz; B.G. Massing; J.H. Davis; C.J.H. Fryer πŸ“‚ Article πŸ“… 1995 πŸ› Elsevier Science 🌐 English βš– 157 KB

F'OS!l'ER ABSTRACTS =0.69), and with pre-harvest bD34+ count (r= 0.56). Peripheral Blood (PB) CD340t cell count and leukocyte count correlated poorly with the CD34+ cell count and CPU-GM of the collected product. We conclude that good correlation exists between PB leukocyte and CD34+ cell count with

Collection efficiencies of MNC subpopula
✍ V. Witt; G. Fischmeister; D. Scharner; D. Printz; U. PΓΆttschger; G. Fritsch; H. πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 157 KB

## Abstract There is increasing demand for mononuclear cell (MNC) harvests not only for PBPC but also for immune therapies using dendritic cells and donor lymphocytes. We determined the collection efficiencies (CE) of various MNC subpopulations during CD34^+^ cell harvests using a Fenwal CS 3000 Pl

Large-volume leukapheresis procedure for
✍ Kanold, Justyna; Halle, Pascale; Berger, Marc; Rapatel, Chantal; Palcoux, Jean B πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Background: We update our experience on large-volume leukapheresis (lvl) in very small patients with malignancies. lvls were performed with the aim of reducing the psychological impact of leukaphereses by reducing the number of procedures while collecting large numbers of cells. ## Procedure:

Autologous peripheral blood progenitor c
✍ Kenneth C. Anderson πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 871 KB

Harvesting of autologous peripheral blood stem cells (PBSCs) has been facilitated by using currently available, efficient apheresis technology at the time of rebound from chemotherapy while patients are receiving recombinant growth factors, i.e., granulocyte (G) or granulocyte-macrophage (GM) colony